Responses
Rheumatoid arthritis
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study
Compose a Response to This Article
Other responses
No responses have been published for this article.